




where the wavy line indicates the site of attachment;

R^8 is selected from $-\text{CH}_3$, $-\text{S}(\text{O})_2\text{CH}_3$, cyclopropyl, azetidin-3-yl, oxetan-3-yl, and

5 morpholin-4-yl;

X^1 is CR^9 or N, where R^9 is selected from H, F, Cl, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, and $-\text{OCH}_2\text{CH}_2\text{OH}$;

X^2 is CR^{10} or N, where R^{10} is selected from H, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, and $-\text{CH}_2\text{CH}_2\text{OH}$;

and

10 Y^1 and Y^2 are independently selected from CH and N, where Y^1 and Y^2 are not each N.

Exemplary embodiments of Formula I compounds include wherein X-X^1 is CR^9 , and R^9 is H.

Exemplary embodiments of Formula I compounds include wherein X-X^1 or X^2 is N.

15 Exemplary embodiments of Formula I compounds include wherein R^4 is $-\text{CH}_2\text{OH}$.

Exemplary embodiments of Formula I compounds include wherein R^2 is F.

Exemplary embodiments of Formula I compounds include wherein R^1 and R^3 are H.

X^2 is CR^{10} or N, where R^{10} is selected from H, $-CH_3$, $-CH_2CH_3$, and $-CH_2CH_2OH$;
and

Y^1 and Y^2 are independently selected from CH and N, where Y^1 and Y^2 are not each N.

2. The compound of claim 1 wherein $\underline{X^1X}$ is CR^9 , and R^9 is H
3. The compound of claim 1 wherein $\underline{X^1}$ or $\underline{X^2X}$ is N.
4. The compound of claim 1 wherein R^4 is $-CH_2OH$.
5. The compound of claim 4 wherein R^2 is F.
6. The compound of claim 5 wherein R^1 and R^3 are H.
7. The compound of claim 1 wherein R^6 is CH_3 .
8. The compound of claim 1 selected from Table 1.
9. The compound of claim 1 selected from Table 2.
10. A pharmaceutical composition comprised of a compound of any one of claims 1 to 9 and a pharmaceutically acceptable carrier, glidant, diluent, or excipient.
11. The pharmaceutical composition according to claim 10, further comprising a therapeutic agent.
12. A process for making a pharmaceutical composition which comprises combining a compound of any one of claims 1 to 9 with a pharmaceutically acceptable carrier.
13. Use of a pharmaceutical composition of claim 10 in the manufacture of a medicament for the treatment of a disease or disorder selected from immune disorders, cancer, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders, and wherein the medicament mediates the Bruton's tyrosine kinase.
14. The use of claim 13 wherein the disease or disorder is an immune disorder.
15. The use of claim 14 wherein the immune disorder is rheumatoid arthritis.
16. The use of claim 13 wherein the disease or disorder is systemic and local inflammation, arthritis, inflammation related to immune suppression, organ transplant rejection, allergies, ulcerative colitis, Crohn's disease, dermatitis, asthma, systemic lupus erythematosus, Sjögren's Syndrome, multiple sclerosis, scleroderma/systemic sclerosis, idiopathic thrombocytopenic purpura (ITP), anti-neutrophil cytoplasmic antibodies (ANCA) vasculitis, chronic obstructive pulmonary disease (COPD), psoriasis.
17. The use of claim 13 wherein the disease or disorder is cancer selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx,